Thinking of Buying Seagen (SGEN)? Here's What You Need to Know.

Shares of Health Care sector company Seagen moved -0.2% today, and are now trading at a price of $212.72. The large-cap stock's daily volume was 1,298,100 compared to its average volume of 1,383,317. The S&P 500 index returned a 1.0% performance.

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company is based in Bothell and has 3,256 full time employees. Its market capitalization is $40,132,395,008.

11 analysts are following Seagen and have set target prices ranging from $228.0 to $229.0 per share. On average, they have given the company a rating of hold. At today's prices, SGEN is trading -7.07% away from its average analyst target price of $228.91 per share.

Over the last year, SGEN's share price has increased by 74.0%, which represents a difference of 60.0% when compared to the S&P 500. The stock's 52 week high is $217.51 per share whereas its 52 week low is $116.08. Seagen has averaged free cash flows of $-244787500.0 over the last 6 years, with a mean growth rate of -20.9%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 -540,151 161,060 -701,211 -32.03
2022 -453,751 77,340 -531,091 3.67
2021 -499,007 52,330 -551,337 -171.22
2020 856,568 82,409 774,159 430.15
2019 -163,737 70,753 -234,490 -4.33
2018 -203,536 21,219 -224,755
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.